Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 OPEN-LABEL, DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE (FORMERLY MDV3100) IN PATIENTS WITH INCURABLE BREAST CANCER

NCT01597193 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01597193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01597193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 OPEN-LABEL, DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE (FORMERLY MDV3100) IN PATIENTS WITH INCURABLE BREAST CANCER
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
January 22, 2018
Enrollment
101 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer